A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.
Epistemonikos ID: 82003bc1fe2f0d6016e5089ffeac3e1862c52291
First added on: Jul 04, 2025